Galmed Pharmaceuticals

Galmed published preclinical data showing that the combination of Aramchol with enzalutamide increased cell death by 3–4‑fold versus enzalutamide alone in a VCaP prostate cancer cell line. The interaction strengthened over time; earlier data had already shown interactions of Aramchol with docetaxel. Galmed plans to engage in talks with potential partners based on a filed patent application and to further evaluate the combination. » More on de.investing.com

Galmed reports that a new oral film formulation of the active substance Aramchol achieves about 150% higher systemic bioavailability and roughly 300% higher central nervous system (CNS) exposure compared with conventional oral administration. The fast‑dissolving film enables buccal/sublingual uptake, reduces first‑pass metabolism and was developed to treat dysphagia in Parkinson’s patients. Aramchol acts as an inhibitor of stearoyl‑CoA desaturase 1 and showed a dose‑dependent reduction of alpha‑synuclein aggregation in earlier in vitro data with a confirmed safety profile. Galmed views the program as partner‑ready and highlights a global Parkinson’s market of more than USD 6 billion. » More on de.investing.com

Galmed reports from a pharmacokinetic phase‑1 study that Aramchol‑Meglumin granulate in single doses shows roughly five‑fold and three‑fold higher bioavailability compared with 300 mg tablets of the free Aramchol acid. The goal is a once‑daily 400 mg dose that could replace ongoing studies using 300 mg twice daily and reduce manufacturing costs by around 50%. The company highlights improved adherence prospects and is also exploring oncological indications; according to InvestingPro the stock appears undervalued at its current valuation and has high short‑term liquidity. » More on de.investing.com